Delivra Health Brands Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Delivra Health Brands şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-13.1%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-13.1%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Health Check: How Prudently Does Harvest One Cannabis (CVE:HVT) Use Debt?

May 29

Did The Underlying Business Drive Harvest One Cannabis' (CVE:HVT) Lovely 345% Share Price Gain?

Feb 11

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: DHB şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: DHB şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Delivra Health Brands Piyasaya Karşı Temettü Getirisi

DHB temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (DHB)	n/a
Pazarın Alt %25'i (CA)	1.8%
Pazarın En İyi %25'i (CA)	6.1%
Sektör Ortalaması (Pharmaceuticals)	2.4%
Analist tahmini (DHB) (3 yıla kadar)	n/a

Önemli Temettü: DHB şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, DHB şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: DHB şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: DHB herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Delivra Health Brands Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

New major risk - Revenue and earnings growth

Delivra Health Brands Inc., Annual General Meeting, Dec 18, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

New minor risk - Profitability

Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.003 loss in 3Q 2023)

Second quarter 2024 earnings released: CA$0.002 loss per share (vs CA$0.004 profit in 2Q 2023)

Delivra Health Brands Inc., Annual General Meeting, Apr 29, 2024

New minor risk - Shareholder dilution

Delivra Health Brands Inc. announced that it has received CAD 0.9 million in funding

Delivra Health Brands Inc. announced that it expects to receive CAD 0.9 million in funding

Delivra Health Brands Inc. announced that it expects to receive CAD 0.9 million in funding

First quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.002 loss in 1Q 2023)

Insufficient new directors

Full year 2023 earnings released: CA$0.001 loss per share (vs CA$0.028 loss in FY 2022)

Delivra Health Brands Inc. to Report Fiscal Year 2023 Results on Oct 18, 2023

Third quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.007 loss in 3Q 2022)

Delivra Health Brands Inc. to Report Q3, 2023 Results on May 23, 2023

Second quarter 2023 earnings released: EPS: CA$0.004 (vs CA$0.006 loss in 2Q 2022)

First quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.006 loss in 1Q 2022)

Full year 2022 earnings released: CA$0.028 loss per share (vs CA$0.09 loss in FY 2021)

Delivra Health Brands Inc. to Report Fiscal Year 2022 Results on Oct 28, 2022

Third quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.005 loss in 3Q 2021)

Harvest One Cannabis Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Harvest One Continues to Expand its Licensed LivRelief InfusedTM Product Line with the Listing of Extra Strength Transdermal CBD Cream at the OCS

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings released: CA$0.13 loss per share (vs CA$0.28 loss in FY 2020)

Health Check: How Prudently Does Harvest One Cannabis (CVE:HVT) Use Debt?

Third quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.17 loss in 3Q 2020)

Harvest One Cannabis Inc. Announces the Launch of Its New LivRelief

Harvest One Cannabis Inc. has completed a Composite Units Offering in the amount of CAD 4.99999 million.

Cann Group Limited (ASX:CAN) completed the acquisition of Satipharm Ltd, Satipharm AG and Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT)

Second quarter 2021 earnings released

Cann Group Limited (ASX:CAN) entered into a definitive sale agreement to acquire Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT).

Cann Group Limited (ASX:CAN) signed a share sale agreement to acquire Satipharm Ltd from Harvest One Cannabis Inc. (TSXV:HVT) for CAD 4 million.

Harvest One Continues International Expansion with Asian Distribution Agreement for Dream Water Products

Did The Underlying Business Drive Harvest One Cannabis' (CVE:HVT) Lovely 345% Share Price Gain?

New 90-day high: CA$0.24

Harvest One Cannabis Inc. Expands Distribution of Dream Water Products in the United States and Internationally

Harvest One Cannabis Inc. Announces Executive Changes

Full year earnings released - CA$0.29 loss per share

An unknown buyer acquired a majority stake in Greenbelt Greenhouse Ltd from Harvest One Cannabis Inc. (TSXV:HVT) for approximately CAD 2.9 million.

Harvest One Cannabis Inc. Announces Management Changes

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin